Doripenem Doribax was to attempt a complex design to evade the issue

The antithrombotic therapy in heart Doripenem Doribax failure is the mortality To reduce t. It is m Possible that the dose of aspirin in the WASH sector was too high, but there are no long term placebo-controlled process Lee aspirin to lower doses in patients with CHD. Heart failure Long term Antithrombotic HELAS study was to attempt a complex design to evade the issue of retention of antithrombotic agents in patients with CHD. He wrote 115 patients with heart failure and LVSD due to CAD and assigned them to aspirin or warfarin and 82 patients who were not considered in order to CAD and ordered them placebo or warfarin. over 22 months, 28 patients died, but only two had a heart attack and five stroke. There was no difference in outcome for the affected group, with patients who had CAD and were assigned to aspirin does slightly worse than other groups. Treatment with warfarin and antiplatelet therapy in the study of chronic heart failure, the Trial Watch on aspirin, a lower dose, clopidogrel 75 mg / day, double-blind label, open, warfarin adjusted to an INR 2.5 to 3.0 . The study was stopped prematurely because of slow recruitment and showed no difference between treatments for the primary Ren endpoint, a composite of death, myocardial infarction or stroke. The reasons for the slow adjustment primarily reflects the reluctance of patients with heart failure to agree to warfarin. The patients assigned to warfarin had a rate of stroke and hospitalization for heart failure, much Similar to the test WASH. Clopidogrel was not as good as warfarin and not quite as bad as aspirin. Whether lower doses of aspirin would have produced a different outcome is unclear. In summary, the results of the study CLOCK is unsatisfactory because, although the fact that warfarin is the best option, suggests, there is not much better than aspirin. If aspirin is ineffective or beautiful harmful, then no antithrombotic therapy for all to see more and more attractive than the preferred option in heart failure. Warfarin versus aspirin in patients with limited Nkter ejection fraction heart This double-blind study, aspirin 325 mg / day and warfarin with a target INR of 2.0 to 3.5 in 2035, compared with patients with heart failure in sinus rhythm and left ventricular rer ejection fraction below 35%. The mean follow-up was 3.5 years. The prime Re endpoint was death or stroke that occurred at a rate of 7.9% per year in the assigned aspirin and 7.5% per year in the assigned warfarin. Prices for the most important secondary Re endpoint was Similar at 12.2% and 12.7% a year. However, the rate fell for a ish Stroke mix by 1.4% in the assigned aspirin and 0.7% per year in the assigned warfarin, w While the rate of major bleeding increased Ht of 0, 9% to 1.8 % per year. This study is best Essentially saturated when set, the results of the WASH and WATCH, although it does not seem to lead to the same signal for hospitalization for heart failure. Clopidogrel versus aspirin in the study of chronic heart failure gr trial comparing aspirin CACHE open-label 75 mg / day and clopidogrel 75 mg / day in 3000 patients with heart failure and an N-terminal pro BNP It as 400 pg / ml . Most of these patients should be treated with diuretics, ACE inhibitors and blockers. The assumption is that aspirin and clopidogrel inhibit both.

Leave a Reply

Your email address will not be published. Required fields are marked *

*

You may use these HTML tags and attributes: <a href="" title=""> <abbr title=""> <acronym title=""> <b> <blockquote cite=""> <cite> <code> <del datetime=""> <em> <i> <q cite=""> <strike> <strong>